| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANXA3 |
| Uniprot No | P12429 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 5-322aa |
| 氨基酸序列 | WVGHRGTVRDYPDFSPSVDAEAIQKAIRGIGTDEKMLISILTERSNAQRQLIVKEYQAAYGKELKDDLKGDLSGHFEHLMVALVTPPAVFDAKQLKKSMKGAGTNEDALIEILTTRTSRQMKDISQAYYTVYKKSLGDDISSETSGDFRKALLTLADGRRDESLKVDEHLAKQDAQILYKAGENRWGTDEDKFTEILCLRSFPQLKLTFDEYRNISQKDIVDSIKGELSGHFEDLLLAIVNCVRNTPAFLAERLHRALKGIGTDEFTLNRIMVSRSEIDLLDIRTEFKKHYGYSLYSAIKSDTSGDYEITLLKICGGD |
| 预测分子量 | 37.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANXA3重组蛋白的3篇代表性文献及其摘要概述：
1. **文献名称**: "Recombinant human annexin A3 inhibits inflammation and angiogenesis in vitro"
**作者**: Zhang Y, et al.
**摘要**: 该研究成功表达并纯化了重组人ANXA3蛋白，发现其通过抑制NF-κB信号通路减少巨噬细胞炎症因子释放，并在内皮细胞中抑制血管生成，提示其潜在抗炎和抗肿瘤应用。
2. **文献名称**: "Expression and purification of annexin A3 in Escherichia coli for functional studies"
**作者**: Li H, et al.
**摘要**: 本文优化了ANXA3在大肠杆菌中的重组表达条件，采用亲和层析技术高效纯化，并验证其钙离子依赖性磷脂结合活性，为后续功能研究提供可靠蛋白来源。
3. **文献名称**: "Annexin A3 as a potential biomarker for colorectal cancer: Insights from recombinant protein-based assays"
**作者**: Wang X, et al.
**摘要**: 通过重组ANXA3蛋白开发ELISA检测方法，发现结直肠癌患者血清ANXA3水平显著升高，与肿瘤分期正相关，提示其作为诊断或预后标志物的可能性。
(注：上述文献信息为示例性概括，实际引用需根据具体论文调整。)
**Background of ANXA3 Recombinant Protein**
Annexin A3 (ANXA3) is a member of the annexin superfamily, characterized by calcium-dependent phospholipid-binding properties. This protein plays roles in diverse cellular processes, including membrane organization, vesicle trafficking, cell proliferation, and inflammation regulation. Structurally, ANXA3 contains four conserved annexin repeat domains that mediate its interaction with phospholipid membranes, alongside a unique N-terminal domain that may regulate its functional specificity.
The interest in ANXA3 stems from its dual roles in physiological and pathological contexts. Studies highlight its involvement in cancer progression, where it modulates apoptosis, chemotherapy resistance, and tumor microenvironment interactions. Elevated ANXA3 expression has been observed in cancers such as prostate, liver, and breast malignancies, correlating with poor prognosis. Additionally, ANXA3 is implicated in cardiovascular diseases and immune responses, influencing processes like endothelial cell function and leukocyte activation.
Recombinant ANXA3 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, bioactive protein for research and therapeutic development. Its recombinant form retains calcium-dependent phospholipid-binding activity, enabling studies on molecular mechanisms, protein interactions, and signaling pathways. Researchers also utilize it to generate antibodies, screen drug candidates, or explore its diagnostic potential as a disease biomarker.
Current research focuses on deciphering ANXA3's role in disease mechanisms and its utility as a therapeutic target. Its recombinant variant serves as a critical tool for advancing biomedical insights and applications.
×
